Searchable abstracts of presentations at key conferences in endocrinology
Previous issue | Volume 49 | ECE2017 | Next issue

19th European Congress of Endocrinology

Lisbon, Portugal
20 May 2017 - 23 May 2017

Card image cap
20-23 May 2017, Lisbon, Portugal Further information

Guided Posters

Diabetes therapy & complications 2

ea0049gp104 | Diabetes therapy & complications 2 | ECE2017

Non-stimulated c-peptide is independently associated with requirement at 1 year for insulin therapy in patients with diabetes: a retrospective cohort study of 872 patients

Leighton Emma , Smith Karen , Sainsbury Christopher , Jones Gregory

Introduction: C-peptide is frequently used in clinical practice to estimate insulin secretion, and guide need for future insulin treatment. Present practice is based on studies with small patient numbers.Aim: To explore the association between non-stimulated c-peptide and progression to insulin therapy in patients with diabetes.Patients and Methods: 1971 patients with c-peptide measurements were identified (February 2007–Decem...

ea0049gp105 | Diabetes therapy & complications 2 | ECE2017

Ceramide synthase 6 inhibition as a novel therapeutic approach for obesity and type 2 diabetes

Bielohuby Maximilian , Prakash Surya , Brunner Bodo , Pfenninger Anja , Werner Ulrich , Turpin-Nolan Sarah , Bruning Jens , Tennagels Norbert

Excess consumption of saturated fatty acids may lead to an increased production of ceramides that contribute to development of insulin resistance and type 2 diabetes. Substantial research demonstrated that inhibition of ceramide biosynthesis ameliorates atherosclerosis, hepatic steatosis, insulin resistance and obesity. However, as ceramides and their sphingolipid products are involved in multiple fundamental cellular processes, concerns exist about possible risks or adverse e...

ea0049gp106 | Diabetes therapy & complications 2 | ECE2017

Outcomes of integrating personal continuous glucose monitors with insulin pumps in a University Diabetes Unit

Rizvi Ali , Smith Kyoka

Objective: Personal continuous glucose monitoring (pCGM) with interstitial fluid glucose sensing is rapidly becoming the standard of care for real-time, intensive insulin therapy of diabetes. We report our experience of glycemic control in patients in an academic setting using minimally invasive pCGM with continuous s.c. insulin infusion (CSII, or insulin pump) vs CSII alone.Methods: Over a two-year period, we reviewed all patients treated with insulin p...

ea0049gp107 | Diabetes therapy & complications 2 | ECE2017

Specific Oct1 gene variants are associated with changes in the risk of cardiovascular death in metformin users

Schweighofer Natascha , Genser Bernd , Marz Winfried , Kleber Marcus E , Pieber Thomas R , Obermayer-Pietsch Barbara

Aim: Increased cardiovascular incidents and a high risk for microvascular complications are associated with type 2 diabetes. Worldwide, metformin is the most commonly prescribed antidiabetic drug. Polymorphisms in the Oct1 gene can alter the function or activity of organic cation transporter 1 (Oct1), thus changing metformin efficacy (Oct1 acting as its main transporter) as well as influencing the actions of Oct1 physiological substrates. In the past, polymorphisms in...

ea0049gp108 | Diabetes therapy & complications 2 | ECE2017

Liraglutide improves carotid intima-media thickness in pre-elderly and elderly patients with type-2 diabetes: an 18-month prospective, real life study

Rizvi Ali , Patti Angelo Maria , Castellino Giuseppa , Mannina Carlo , Nikolic Dragana , Giglio Rosaria Vincenza , Chianetta Roberta , Montalto Giuseppe , Rizzo Manfredi

Introduction: Liraglutide exerts cardio-protective effects beyond of those on glucose metabolism, affecting several cardio-metabolic parameters, such as subclinical atherosclerosis. However, it is not known if those effects differ in the long-term between pre-elderly and elderly subjects with type-2 diabetes (T2DM).Methods: We included 135 subjects with T2DM divided in 2 groups: i) 71 pre-elderly subjects (46 men and 25 women, 55±7 years), and ii) 6...

ea0049gp109 | Diabetes therapy & complications 2 | ECE2017

Treatment of diabetic ketoacidosis at type 1 diabetes mellitus presentation: 13 year experience from a tertiary centre (2004–2016)

Serra-Caetano Joana , Gata Lia , Dinis Alexandra , Cardoso Rita , Dinis Isabel , Patricio Miguel , Mirante Alice

Introduction: Diabetic ketoacidosis (DKA) is an endocrine emergency and the leading cause of morbi-mortality in children with type 1 diabetes mellitus (1DM). DKA treatment is still controverse, mainly regarding hydroelectrolytic replacement and insulin dose.Aims: To evaluate efectiveness and safety of our tertiary centre protocol in DKA treatment, which included initial volume expansion with isotonic saline in the first two hours followed by 0.45% sodium...

ea0049gp110 | Diabetes therapy & complications 2 | ECE2017

The method of reporting hypoglycemia in Randomized Control Trials (RCTs): a systematic review on RCTs conducted for SGLT-2 inhibitors

Kassir Noor , Medeiros Sarah , Farahani Pendar

Background: Hypoglycemia is an important side effect in pharmacotherapy of patients with diabetes mellitus. Medical organizations have tried to define hypoglycemia in clinical practice and RCTs with scientific statements and guidelines.Objective: To explore the method of reporting hypoglycemia conducted on SGLT-2 inhibitor RCTs.Methods: A systematic review using PubMed to find data on RCTs conducted for SGLT-2 inhibitors, limited t...

ea0049gp111 | Diabetes therapy & complications 2 | ECE2017

Hepatic effects of GLP-1 receptor agonist Liraglutide in patients with type 2 diabetes

Hayon Maria , Fernandez Marta , Maraver Silvia , Muros Teresa , Cepero Daniel , Lopez Martin , Quesada Miguel , Pechuan Joaquin , Piedrola Gonzalo

Introduction: The aim of this study was to analyze the effects of Liraglutide in hepatic steatosis as well as clinical and biochemical data before and after 6 months.Methods: We have retrospectively analysed epidemiological, anthropometric and laboratory data of 83 type 2 diabetic patients treated with Liraglutide and followed at different endocrinology units across east Andalusia. We have evaluated nonalcoholic fatty liver disease using liver enzymes an...

ea0049gp112 | Diabetes therapy & complications 2 | ECE2017

Exenatide treatment causes suppression of serum fasting ghrelin levels in patients with type 2 diabetes Mellitus

Guclu Metin , Kiyici Sinem , Gul Zulfiye , Cavun Sinan

Aim: Ghrelin plays an important role in the stimulation of food intake and long-term regulation of body weight. In present study we investigate the long term effect of exenatide treatment on serum fasting ghrelin levels in patients with type 2 diabetes mellitus.Methods: Type 2 diabetic patients who were using metformin with and without the other oral antihiperglycemic drugs on a stable dose for at least 3 months were enrolled in the study. Body mass inde...